Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Correlation of Midkine Serum Level With Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis Pubmed



Shaygannejad V1 ; Montazeri S2 ; Jamshidian A3 ; Tahani S1, 5 ; Gharagozloo M4 ; Ashtari F1 ; Vesal S1 ; Hasheminia SJ5 ; Dehghani L1, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology and Isfahan Neurosciences Research Center, Iran
  2. 2. Medical Student Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Immunology and Microbiology Department, Shahrekord University of Medical Sciences, Shahrekord, Iran
  4. 4. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Iran
  5. 5. Department of Medical Sciences, Najafabad Branch, Islamic Azad University, Isfahan, Iran

Source: Iranian Journal of Immunology Published:2014


Abstract

Background: Midkine (MK) is a heparin-binding growth factor with promoting effects in inflammatory responses through enhancing leukocytes migration. Objective: To study the correlation between MK serum levels and concentration of inflammatory cytokines in Multiple Sclerosis (MS) patients. Methods: We evaluated the MK level and its relationship with inflammatory cytokines (IL-17 and IL-23) and antiinflammatory ones (IL-10 and TGF-β) in multiple sclerosis (MS) patients. The serum concentrations of MK and cytokines were assessed by ELISA in 32. MS patients in comparison with 32 healthy subjects. Results: Our data showed that the MK concentration in MS patients is lower than healthy controls (341.15 ± 40. 71. Pg/ml vs. 620.15 ± 98. 61. Pg/ml, respectively, p=0.015). We also observed a significant decrease in IL-10, IL-23, and TGF-β cytokine levels in MS patients. There was a significant correlation between MK and IL-23 concentrations in our study (r = +0.829, p≤ 0.001). Conclusion: These results confirm a role for MK in inflammatory reactions in MS. © 2014 (Shiraz University of Medical Sciences). All Rights reserved.
Related Docs
View other Related Docs
1. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
2. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)
3. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
4. Decreased Serum Levels of Interleukin-35 Among Multiple Sclerosis Patients May Be Related to Disease Progression, Journal of Biological Regulators and Homeostatic Agents (2018)
5. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
6. Tnf-Alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls, Immunological Investigations (2015)
7. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial, International Immunopharmacology (2021)
8. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (60)
Vahid Shaygannejad (46)
Other Related Docs
9. Evaluating the Effects of Epigallocatechin-3-Gallate on Hif-1Α Protein and Rorc Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
10. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
11. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
12. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
13. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
14. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
15. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
16. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
17. Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial, NeuroImmunoModulation (2014)
18. Evaluation of Plasma Osteopontin Level in Relapsing- Remitting Multiple Sclerosis Patients Compared to Healthy Subjects in Isfahan Province, International Journal of Neuroscience (2020)
19. Leptin Hormone Level in Serum of Opticospinal, Neuromyelitisoptica and Multiple Sclerosis Patients, Clinical and Experimental Neuroimmunology (2014)
20. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
21. Vitamin D Supplementation Could Limit T Helper-17 Response in Multiple Sclerosis, Clinical and Experimental Neuroimmunology (2014)
22. Interleukin 18 Polymorphisms and Its Serum Level in Patients With Multiple Sclerosis, Annals of Indian Academy of Neurology (2019)
23. Association of Interleukin-1 Gene Cluster Polymorphisms and Haplotypes With Multiple Sclerosis in an Iranian Population, Journal of Neuroimmunology (2015)
24. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
25. Evaluation of Matrix Metalloproteinase-9 Plasma Levels in Untreated New Relapsing–Remitting Multiple Sclerosis Patients and Their First-Degree Family, Metabolic Brain Disease (2021)
26. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
27. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, Iranian Journal of Immunology (2014)
28. Effect of High Dose Vitamin D Intake on Interleukin-17 Levels in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Neuroimmunology (2015)
29. Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2015)
30. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
31. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
32. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
33. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
34. Elevated Serum Level of Il-4 in Neuromyelitis Optica and Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
35. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
36. Evaluation of the Frequency of Osteopontin Gene Polymorphism (Rs28357094 T>G) and Its Receptor Gene (Itga4- Rs1449263 A>G) in Multiple Sclerosis Patients in Comparison to Healthy Controls in Isfahan, Iran, Population, Journal of Isfahan Medical School (2016)
37. Expression of Chemokine Receptors on Th1/Th2 Cd4+ Lymphocytes in Patients With Multiple Sclerosis, Iranian Journal of Immunology (2011)
38. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
39. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
40. Elevated Csf Concentration of Ccl3 and Ccl4 in Relapsing Remitting Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
41. The Global Prevalence of Familial Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis, BMC Neurology (2021)
42. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
43. Therapeutic Plasma Exchange May Adjust Il-6 and Tgf-Β Signals in Relapsed Ms Patients Peripheral Blood, Journal of Clinical Apheresis (2020)
44. Prenatal and Perinatal Factors Associated With Developing Multiple Sclerosis Later in Life: A Systematic Review and Meta-Analysis, Autoimmunity Reviews (2021)
45. Comparing the Frequency of Tim-3 Polymorphism in Multiple Sclerosis Patients With Healthy Controls, Journal of Isfahan Medical School (2015)
46. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
47. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
48. Optimization of Human Th17 Cell Differentiation in Vitro: Evaluating Different Polarizing Factors, In Vitro Cellular and Developmental Biology - Animal (2011)
49. Current Advances in Stem Cell Therapy in the Treatment of Multiple Sclerosis, Reviews in the Neurosciences (2023)
50. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)